Jackson Financial, Inc. (JXN)
NYSEFinancialsInsurance - LifeSnapshot 2026-10-30
NYSEFinancialsInsurance - LifeSnapshot 2026-10-30
Research Workspace
Put JXN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRanks among the strongest in its industry on quality — around the top 13%.
View QualityManagement screens weak on capital allocation, earnings delivery.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskJackson Financial’s thesis rests on meeting its 2026 free cash flow commitment despite reinsurer concerns. Recent revenue growth is unavailable, and the latest recorded quarter beat had no revenue data. The prior quarter missed, with non-GAAP EPS down 13.6% versus expectations. JXN trades at 0.9× P/B versus a 1.3× peer median. Expectations look modest versus our view, though reinsurer concerns threaten the cash flow goal. Our model puts the next-quarter miss probability near 26%. Management is behind on a stated commitment, and peer multiples imply a price about 50% above where it trades. The read is provisional.
Trailing returns as of 2026-10-30. JXN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 4 analysts currently covering JXN (as of Oct 2026).
Based on 3 Wall Street analysts offering 12-month price targets for JXN in the last 4 months.
Continue this research
Compare JXN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| JXN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life & Health Insurance — fair value, gap to price, and forward P/E.
Compare the value case
Put JXN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Achieve $1.2 billion or more Free Cash Flow in 2026
Reinsurer concerns could impact cash flow targets.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $134.93
The last 12 months of price, then the range of analyst 12-month targets from today’s $134.93.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers

Threatens: Achieve $1.2 billion or more Free Cash Flow in 2026
Reinsurer concerns could impact cash flow targets.
